/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

VolitionRX Ltd share price today is $0.1961, up -3.26%. The stock opened at $0.207 against the previous close of $0.2027, with an intraday high of $0.207 and low of $0.1922.

style

pb-0

VolitionRX Ltd

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$0.1961 -0.0326(-3.26%) VNRX at 13 Mar 2026 03:47 PM Medical Devices

Lowest Today 0.1922

Highest Today 0.207

Today’s Open 0.207

Prev. Close 0.2027

52 Week High 0.94

52 Week Low 0.17

Day’s Range: Low 0.1922 High 0.207

52-Week Range: Low 0.17 High 0.94

VolitionRX Ltd Institutional Holdings

VolitionRX Ltd Market Status

Strong Buy: 3

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

VolitionRX Ltd Fundamentals

Market Cap 27.48 M

PB Ratio 38.4366

PE Ratio 0.0

Enterprise Value 38.17 M

Total Assets 9.40 M

Volume 684279

VolitionRX Ltd Company Financials

Annual Revenue FY23:651044 0.7M, FY22:306392 0.3M, FY21:90035 0.1M, FY20:13433 0.0M, FY19:17096 0.0M

Annual Profit FY23:null 0.0M, FY22:306392 0.3M, FY21:90035 0.1M, FY20:13433 0.0M, FY19:17096 0.0M

Annual Net worth FY23:-33862924 -33.9M, FY22:-30268793 -30.3M, FY21:-26970468 -27.0M, FY20:-20481914 -20.5M, FY19:-16028670 -16.0M

Quarterly Revenue Q3/2025:627277 0.6M, Q2/2025:406688 0.4M, Q1/2025:246385 0.2M, Q3/2024:474522 0.5M, Q2/2024:395797 0.4M

Quarterly Profit Q3/2025:627277 0.6M, Q2/2025:406688 0.4M, Q1/2025:246385 0.2M, Q3/2024:474522 0.5M, Q2/2024:72000 0.1M

Quarterly Net worth Q3/2025:-5378358 -5.4M, Q2/2025:-6284078 -6.3M, Q1/2025:-5423759 -5.4M, Q3/2024:-5821529 -5.8M, Q2/2024:-6985546 -7.0M

About VolitionRX Ltd & investment objective

Company Information VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is based in Henderson, Nevada.

Organisation Medical Devices

Employees 75

Industry Medical Devices

CEO Mr. Cameron Reynolds MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*